lintuzumab + mitoxantrone + etoposide + cytarabine

This is a **four-drug combination regimen** composed of lintuzumab, mitoxantrone, etoposide, and cytarabine, investigated primarily for the treatment of **acute myeloid leukemia (AML)** and high-risk myeloid malignancies. - **Lintuzumab** is a humanized monoclonal antibody targeting **CD33**, an antigen expressed on myeloid leukemia cells, designed to mediate antitumor effects via immune mechanisms. - **Mitoxantrone** is an **anthracenedione** antineoplastic agent that intercalates into DNA and inhibits topoisomerase II, causing DNA strand breaks and impaired replication. - **Etoposide** is a **topoisomerase II inhibitor** that prevents DNA unwinding and cell division, leading to apoptosis in proliferating cells. - **Cytarabine** (also called Ara-C) is an **antimetabolite** (cytidine analog) that interferes with DNA synthesis, specifically affecting cells in the S phase of the cell cycle. This regimen is used primarily in clinical trial or salvage settings for relapsed or refractory AML. The combination is intended to maximize cytotoxicity against leukemic cells by acting through multiple complementary mechanisms and pathways.